Dyne Therapeutics
113 hedge funds and large institutions have $571M invested in Dyne Therapeutics in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 9 closing their positions.
1,655% more call options, than puts
Call options by funds: $860K | Put options by funds: $49K
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
11% more funds holding
Funds holding: 102 → 113 (+11)
7.82% more ownership
Funds ownership: 87.56% → 95.38% (+7.8%)
9% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less capital invested
Capital invested by funds: $573M → $571M (-$1.79M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$26.9M |
| 2 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
+$10.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.8M |
| 4 |
Goldman Sachs
New York
|
+$5.07M |
| 5 |
Axa
Paris,
France
|
+$4.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$19.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$5.79M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$2.24M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.59M |
| 5 |
Citigroup
New York
|
-$1.35M |
DYN Hedge Fund Activity: Q4 2022 in Review
113 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q4 2022, worth a combined $571M — down 0.31% from $573M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new DYN positions and 9 closed out — a net gain of 12 holders — while 37 added to existing stakes and 34 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $26.9M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $19.5M sold.
- 113 institutional investors held Dyne Therapeutics (DYN) as of Q4 2022, up from 102 in Q3 2022.
- Funds reported $571M of Dyne Therapeutics stock for Q4 2022, down 0.31% quarter-over-quarter.
- 21 funds opened new Dyne Therapeutics positions in Q4 2022 and 9 closed out, a net change of +12 holders.
- The largest Dyne Therapeutics buyer in Q4 2022 was EcoR1 Capital, an estimated $26.9M added.
- The largest Dyne Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $19.5M sold.
Based on aggregated 13F filings for Q4 2022.